Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (364)	7/28/1999 4:38:00 PM
From: John Dwyer	Read Replies (1) \| Respond to of 399

Look, I just don't want to hear another "butt" analogy from Rick, that's all... ;^) My point with the patent issue is that SEPR is developing an improved version of the same (patented) stuff. ARQL is (hopefully) coming up with novel molecules. That ARQL is focusing solely on combichem means they are assuming that they can retain competitive advantage over all other combichem programs, both in-house at big pharma and outside. I haven't seen too much "value-added" coming out of ARQL. I like PCOP and ABSC because of their additional services which they can use in-house or offer to other companies in conjunction with combichem, UHTSS, etc. ABSC has a really nice assay development program which I think is potentially very valuable. John